| __timestamp | MorphoSys AG | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 504755000 |
| Thursday, January 1, 2015 | 10431000 | 838526000 |
| Friday, January 1, 2016 | 9618000 | 1177697000 |
| Sunday, January 1, 2017 | 12348000 | 1320433000 |
| Monday, January 1, 2018 | 28310241 | 1556200000 |
| Tuesday, January 1, 2019 | 59336147 | 1834800000 |
| Wednesday, January 1, 2020 | 159145941 | 1346000000 |
| Friday, January 1, 2021 | 199800000 | 1824900000 |
| Saturday, January 1, 2022 | 90225000 | 2115900000 |
| Sunday, January 1, 2023 | 92538000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unlocking the unknown
In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Regeneron Pharmaceuticals, Inc. and MorphoSys AG from 2014 to 2023. Over this period, Regeneron consistently outspent MorphoSys, with its SG&A expenses peaking at approximately $2.63 billion in 2023, a staggering 2,740% higher than MorphoSys's $92.5 million. This trend highlights Regeneron's aggressive investment in administrative and sales functions, potentially fueling its market dominance. Meanwhile, MorphoSys's expenses, though modest, have shown a steady increase, reflecting its strategic growth efforts. The data underscores the contrasting financial strategies of these biotech giants, offering insights into their operational priorities and market positioning.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: AbbVie Inc. vs Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. vs Ascendis Pharma A/S: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Genmab A/S vs MorphoSys AG
BioMarin Pharmaceutical Inc. and MorphoSys AG: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and MorphoSys AG
Comparing SG&A Expenses: MorphoSys AG vs Ligand Pharmaceuticals Incorporated Trends and Insights